Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $60.07, up 7.31%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RYTM shares have gain 7.56% over the last week, with a monthly amount drifted -1.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on January 02, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $80. Previously, Oppenheimer started tracking the stock with Outperform rating on December 20, 2024, and set its price target to $76. On October 21, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $70 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $64 on September 18, 2024. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $64 as its price target on September 17, 2024. BofA Securities downgraded its rating to Neutral for this stock on May 08, 2024, and downed its price target to $42. In a note dated December 19, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $29 to $55.
Rhythm Pharmaceuticals Inc [RYTM] stock has fluctuated between $35.17 and $68.58 over the past year. Currently, Wall Street analysts expect the stock to reach $67.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $60.07 at the most recent close of the market. An investor can expect a potential return of 12.54% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 112.53M for the trailing twelve months, which represents a growth of 47.76%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -2.36%, Pretax Profit Margin comes in at -2.3%, and Net Profit Margin reading is -2.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -3.69 and Total Capital is -1.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 57.56 points at the first support level, and at 55.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 61.55, and for the 2nd resistance point, it is at 63.03.
Ratios To Look Out For
For context, Rhythm Pharmaceuticals Inc’s Current Ratio is 3.49. Also, the Quick Ratio is 3.34, while the Cash Ratio stands at 0.49. Considering the valuation of this stock, the price to sales ratio is 32.81, the price to book ratio is 329.06.
Transactions by insiders
Recent insider trading involved Lee Jennifer Kayden, EVP, Head of North America, that happened on Nov 11 ’24 when 66861.0 shares were sold. Chief Technical Officer, Shulman Joseph completed a deal on Nov 11 ’24 to sell 13281.0 shares. Meanwhile, Officer JENNIFER KAYDEN LEE bought 66861.0 shares on Nov 11 ’24.
